BMK vs. AMYT, APH, AGY, BXP, ANCR, EAH, CEL, DNL, STX, and PXS
Should you be buying Benchmark stock or one of its competitors? The main competitors of Benchmark include Amryt Pharma (AMYT), Alliance Pharma (APH), Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), Celadon Pharmaceuticals (CEL), Diurnal Group (DNL), Shield Therapeutics (STX), and Provexis (PXS). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Amryt Pharma (LON:AMYT) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings.
Amryt Pharma has a net margin of 0.00% compared to Amryt Pharma's net margin of -18.96%. Benchmark's return on equity of 0.00% beat Amryt Pharma's return on equity.
91.8% of Benchmark shares are held by institutional investors. 5.8% of Benchmark shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Amryt Pharma has higher revenue and earnings than Benchmark. Benchmark is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Benchmark had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Benchmark and 0 mentions for Amryt Pharma. Benchmark's average media sentiment score of 0.00 beat Amryt Pharma's score of -1.19 indicating that Amryt Pharma is being referred to more favorably in the media.
Amryt Pharma received 7 more outperform votes than Benchmark when rated by MarketBeat users. However, 72.62% of users gave Benchmark an outperform vote while only 65.68% of users gave Amryt Pharma an outperform vote.
Summary
Amryt Pharma beats Benchmark on 7 of the 12 factors compared between the two stocks.
Get Benchmark News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benchmark Competitors List
Related Companies and Tools
